UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia

被引：5

作者：

Iurlo, Alessandra ^{[1
]}

Bucelli, Cristina ^{[1
]}

Cattaneo, Daniele ^{[1
]}

Levati, Giorgia Virginia ^{[1
]}

Viani, Benedetta ^{[1
]}

Tavazzi, Dario ^{[2
,3
]}

Consonni, Dario ^{[4
]}

Baldini, Luca ^{[1
]}

Cappellini, Maria Domenica ^{[2
,3
]}

机构：

[1] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hematol Div, Milan, Italy

[2] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy

[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Epidemiol Unit, Milan, Italy

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2019年 / 94卷 / 11期

关键词：

RECOMMENDATIONS; CHEMOTHERAPY; MANAGEMENT; NILOTINIB;

D O I：

10.1002/ajh.25596

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E283 / E285

页数：3

共 50 条

[31] Intolerance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Definitions and Clinical Implications [J].

Pinilla-Ibarz, Javier ;

Cortes, Jorge ;

Mauro, Michael J. .

CANCER, 2011, 117 (04) :688-697

[32] Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations [J].

Abruzzese, Elisabetta ;

Mauro, Michael ;

Apperley, Jane ;

Chelysheva, Ekaterina .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11

[33] Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia [J].

Ghanem, Hady ;

Kantarjian, Hagop ;

Cortes, Jorge ;

Quintas-Cardama, Alfonso ;

Jabbour, Elias .

EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (08) :607-623

[34] Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia [J].

Toker, Michelle ;

Jaller, Jose A. ;

Delbourgo Patton, Caroline ;

Wu, Benedict .

PEDIATRIC DERMATOLOGY, 2024, 41 (01) :169-176

[35] Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia [J].

Aleem, Aamer ;

Alotaibi, Ghazi ;

Iqbal, Zafar ;

AlFaifi, Abrar .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (02) :288-291

[36] Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia [J].

Swords R. ;

Alvarado Y. ;

Cortes J. ;

Giles F.J. .

Current Hematologic Malignancy Reports, 2007, 2 (2) :83-88

[37] New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia [J].

Almeida, Ana G. ;

Almeida, Antonio ;

Melo, Teresa ;

Guerra, Lurdes ;

Lopes, Luis ;

Ribeiro, Patricia ;

Duarte, Marta ;

Mota, Alexandra ;

Fontes-Carvalho, Ricardo .

REVISTA PORTUGUESA DE CARDIOLOGIA, 2019, 38 (01) :1-9

[38] Influence of UGT1A1*6,*27, and*28 Polymorphisms on Nilotinib-induced Hyperbilirubinemia in Japanese Patients with Chronic Myeloid Leukemia [J].

Abumiya, Maiko ;

Takahashi, Naoto ;

Niioka, Takenori ;

Kameoka, Yoshihiro ;

Fujishima, Naohito ;

Tagawa, Hiroyuki ;

Sawada, Kenichi ;

Miura, Masatomo .

DRUG METABOLISM AND PHARMACOKINETICS, 2014, 29 (06) :449-454

[39] Comparative efficacy and safety of first-line tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and network meta-analysis [J].

Zhang, Jing-Jing ;

Qian, Yu-Lan ;

Wu, Zi-Yang ;

Li, Yue ;

Guan, Ying-Jie ;

Sun, Cui ;

Fu, Kai-Li ;

Mei, Tong-Lin ;

Goyal, Gaurav ;

Bernasconi, Paolo ;

Damiani, Daniela ;

Zhu, Jian-Guo .

TRANSLATIONAL CANCER RESEARCH, 2024, 13 (07)

[40] Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors [J].

Erbilgin, Yucel ;

Eskazan, Ahmet Emre ;

Ng, Ozden Hatirnaz ;

Salihoglu, Ayse ;

Elverdi, Tugrul ;

Firtina, Sinem ;

Tasar, Orcun ;

Mercan, Sevcan ;

Sisko, Sinem ;

Khodzhaev, Khusan ;

Ongoren, Seniz ;

Ar, Muhlis Cem ;

Baslar, Zafer ;

Soysal, Teoman ;

Sayitoglu, Muge ;

Ozbek, Ugur .

LEUKEMIA & LYMPHOMA, 2019, 60 (01) :200-207

← 1 2 3 4 5 →